The large size of the coronavirus (CoV) genome (around 30 kb) and the instability in bacteria of plasmids carrying CoV replicase sequences represent serious restrictions for the development of CoV infectious clones using reverse genetic systems similar to those used for smaller positive sense RNA viruses. To overcome these problems, several approaches have been established in the last 13 years. Here we describe the engineering of CoV full-length cDNA clones as bacterial artifi cial chromosomes (BACs), using the Middle East respiratory syndrome CoV (MERS-CoV) as a model.
Introduction
Coronaviruses (CoV) are enveloped, single-stranded, positivesense RNA viruses relevant in animal and human health [ 1 , 2 ] . Historically, CoV infection in humans has been associated with mild upper respiratory tract diseases [ 1 ] . However, the identifi cation of the severe acute respiratory syndrome CoV (SARS-CoV) in 2003 [ 3 ] and the recently emerged (April 2012) Middle East respiratory syndrome CoV (MERS-CoV) [ 4 ] , which has been associated with acute pneumonia, redefi ned historic perceptions and potentiated the relevance of CoVs as important human pathogens. In this sense, the development of CoV infectious clones provides a valuable molecular tool to study fundamental viral processes, to develop genetically defi ned vaccines, and to test antiviral drugs. However, the generation of CoV infectious clones has been hampered for a long time due to the huge size of the CoV genome (around 30 kb) and the toxicity of some CoV replicase gene sequences during its propagation in bacteria. Recently, these problems were overcome using nontraditional approaches based on the use of bacterial artifi cial chromosomes (BACs) [ 5 ] , in vitro ligation of cDNA fragments [ 6 ] , and vaccinia virus as a vector for the propagation of CoV full-length cDNAs [ 7 , 8 ] .
In this chapter we describe the protocol to assemble CoV fulllength cDNAs in BACs using the MERS-CoV EMC12 strain [ 9 ] as an example. In this system, the full-length cDNA copy of the viral genome is assembled in the BAC plasmid pBeloBAC11 [ 10 ] ( Fig. 1 ) , a low-copy-number plasmid based on the Escherichia coli ( E. coli ) F-factor [ 11 ] that presents a strictly controlled replication leading to one or two plasmid copies per cell. This plasmid minimizes the instability problem of several CoV sequences when amplifi ed in high-copy-number plasmids, allows the stable maintenance of large DNA fragments in bacteria [ 11 ] , and its manipulation is similar to that of conventional plasmids. The cDNA of the CoV genome is assembled in the BAC under the control of the cytomegalovirus (CMV) immediate-early promoter and it is fl anked at the 3ʹ-end by a 25-bp synthetic poly(A) followed by the sequences of the hepatitis delta virus (HDV) ribozyme and the bovine growth hormone (BGH) termination and polyadenylation signals to produce synthetic RNAs bearing authentic 5ʹ-and 3ʹ-ends of the viral genome. This DNA-launched system couples expression of the viral RNA in the nucleus from the CMV promoter [ 12 ] with a second amplifi cation step in the cytoplasm driven by the viral polymerase, allowing the recovery of infectious virus from the cDNA clone without the need for in vitro ligation and transcription steps. Although some splicing events could occur during the nuclear expression of the viral genome, the effi ciency of this phenomenon is very low and does not affect the recovery of infectious virus [ 5 ] .
The BAC approach, originally applied to the transmissible gastroenteritis coronavirus (TGEV) [ 5 ] , has been successfully used to engineer the infectious clones of the feline infectious peritonitis virus (FIPV) [ 13 ] and the human CoVs (HCoVs): HCoV-OC43 [ 14 ] ,
Fig. 1
Schematic of plasmid pBeloBAC11. The regulatory genes parA , parB , parC , and repE , the F-factor replication origin ( OriS ), the chloramphenicol resistance gene ( Cm r ), the lacZ gene, and the restriction sites that can be used to clone foreign DNAs are indicated SARS-CoV [ 15 ] , and MERS-CoV [ 16 ] , and it is potentially applicable to the cloning of other CoV cDNAs, other viral genomes, and large-size RNAs of biological relevance.
Materials
To reach optimal results, all solutions should be prepared using pure Milli-Q grade water (resistivity of 18.2 MΩ/cm at 25 °C) and analytical grade reagents.
Methods
The basic strategy for the generation of CoV infectious clones using BACs is described for the MERS-CoV EMC12 strain (GenBank accession number JX869059) [ 9 ] as a model (Fig. 2 ).
1. The fi rst step for the assembly of the full-length cDNA clone is the selection of appropriate restriction endonuclease sites in the viral genome. These restriction sites must be absent in the BAC plasmid ( see Note 4 ). In the case of MERS-CoV, the restriction sites BamHI (genomic position 806), StuI (genomic positions 7,620 and 9,072), SwaI (genomic position 20,898), and PacI (genomic position 25,836) were selected to assemble the infectious clone ( Fig. 2 ). 2. In case that no adequate restriction sites were available in the viral genome, new restriction sites, appropriately spaced in the viral genome, could be generated by the introduction of silent mutations. In addition, natural restriction sites could be eliminated following the same approach to facilitate the assembly of the infectious clone ( see Note 5 ).
Assembly of Full-Length CoV cDNAs in BACs
The assembly of the infectious clone in a BAC is facilitated by the construction of an intermediate BAC plasmid containing the 5ʹ-end of the genome (until the fi rst restriction site selected) under the control of the CMV promoter, a multicloning site containing the restriction sites selected in the fi rst step, and the 3ʹ-end of the genome (from the last restriction site selected to the end of the genome) followed by a 25-nt poly(A) tail, the HDV ribozyme, and the BGH termination and polyadenylation sequences. All these elements have to be precisely assembled to produce synthetic RNAs bearing authentic 5ʹ-and 3ʹ-ends of the viral genome. A detailed protocol for the generation of the MERS-CoV intermediate plasmid, pBAC-MERS-CoV 5ʹ-3ʹ, is described next (Fig. 2 ).
1. Generate by chemical synthesis a DNA fragment containing the CMV promoter [ 12 ] precisely fused to the fi rst 811 nt of the viral genome (from the fi rst nucleotide to the restriction site BamHI), fl anked at the 5ʹ-and 3ʹ-ends by restriction sites SfoI and BamHI, respectively. Alternatively, this DNA fragment could be generated by PCR using two overlapping PCR fragments as template ( see Notes 6 and 7 ). One of these fragments should contain the CMV promoter fl anked at the 5ʹ-end by the restriction site SfoI and at the 3ʹ-end by the 20 fi rst nucleotides of the genome as overlapping sequence. The second overlapping PCR fragment should expand from the fi rst nucleotide to the restriction site BamHI.
2. The generated DNA fragment is digested with SfoI and BamHI, and cloned into pBeloBAC11 -StuI digested with the same restriction enzymes to generate the plasmid pBAC-MERS-CoV 5ʹ.
3. Generate a second DNA fragment, containing the last 4,272 nt of the viral genome (from the restriction site PacI at genomic position 25,836 to the end of the genome) precisely joined to a 25-nt poly(A) tail, the HDV ribozyme, and the BGH termination and polyadenylation sequences, fl anked at the 5ʹ-end by a multicloning site with the restriction sites selected before (BamHI, StuI, SwaI, and PacI) and at the 3ʹ-end by the restriction site Sfi I. This DNA fragment could be generated by chemical synthesis or by overlapping PCR as described before ( see Notes 6 and 7 ).
Digest with
BamHI and Sfi I the second DNA fragment (containing the multicloning site, the viral 3ʹ-end followed by the 2. The overlapping DNAs fl anked by the appropriated restriction sites are generated either by chemical synthesis or by standard reverse transcriptase PCR (RT-PCR) ( see Note 6 ) using specifi c oligonucleotides and total RNA from infected cells as template. In the case of fragment MERS-3, a silent mutation (T to C) was introduced at position 20,761 to abrogate the SwaI restriction site at position 20,760. This mutation facilitates the cloning process and can be used as a genetic marker to identify the virus recovered from the full-length cDNA clone.
3. The genetic integrity of the cloned DNAs is verifi ed throughout the subcloning and assembly process by extensive restriction analysis and sequencing.
One of the major advantages of using BAC vectors to generate infectious clones is that the manipulation of BAC clones is relatively easy and essentially the same as that of a conventional plasmid with slight modifi cations due to the huge size of the BAC clones and the presence of this plasmid in only one or two copies per cell [ 11 ] . The amplifi cation and isolation of BAC plasmids is performed using standard procedures described for conventional plasmids but using large volumes of bacterial cultures.
Small amounts of BAC DNAs are prepared from 5 ml cultures of BAC transformed DH10B cells by the alkaline lysis method. Any commercial kit could be used, but we suggest the QIAprep Miniprep Kit (Qiagen) following the recommendations for purifi cation of large low-copy plasmids.
1. Streak the bacterial stock containing the BAC plasmid onto a LB agar plate containing 12.5 µg/ml chloramphenicol and incubate for 16 h at 37 °C ( see Note 9 ).
2. Inoculate a single colony in 5 ml of LB medium plus 12.5 µg/ml chloramphenicol in a fl ask with a volume of at least four times the volume of the culture and incubate for 16 h at 37 °C with vigorous shaking (250 rpm) ( see Note 10 ).
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Generation and Manipulation of BAC Clones
Isolation of BAC Plasmids from Small-Scale Cultures
3. Harvest the bacterial cells in 15 ml centrifuge tubes by centrifugation at 6,000 × g for 10 min at 4 °C and pour off the supernatant fl uid.
4. Purify the BAC plasmid following the manufacturer's instructions. Owing to the size of BAC DNAs and the need to use large culture volumes, we recommend duplicating the volume of buffers P1, P2, and N3, performing the optional wash step with buffer PB, and eluting the DNA from the QIAprep membrane using buffer EB preheated at 70 °C ( see Note 11 ). Owing to the large size of BAC plasmids, the cloning of DNA fragments in BACs requires the use of DH10B competent cells with transformation effi ciencies higher than 1 × 10 8 transformant colonies per µg of DNA. These effi ciencies are easily obtained by the electroporation method, which is more reproducible and effi cient than the chemical methods. Here we described the protocol for preparing electrocompetent DH10B cells from 1 l of bacterial culture. All the steps of this protocol should be carried out under sterile conditions. 2. Dilute 1 ml of the overnight culture into 1 l of SOB medium pre-warmed at 37 °C and grow the cells with vigorous shaking (250 rpm) in a 2 l fl ask at 37 °C until the OD at 550 nm reaches 0.7 (this can take 4-5 h) ( see Note 14 ).
3. Transfer the fl ask to an ice-water bath for about 20 min. Swirl the culture occasionally to ensure that cooling occurs evenly. From this point on, it is crucial that the temperature of the bacteria not rise above 4 °C.
4. Divide the bacteria culture in two ice-cold 500 ml centrifuge bottles and harvest the cells by centrifugation at 6,000 × g for 10 min at 4 °C. Discard the supernatant and resuspend each cell pellet in 500 ml of ice-cold 10 % glycerol in sterile water.
5.
Harvest the cells by centrifugation at 6,000 × g for 15 min at 4 °C. Carefully pour off the supernatant and resuspend each cell pellet in 250 ml of ice-cold 10 % glycerol ( see Note 15 ).
6. Repeat step 5 reducing the resuspension volume to 125 ml from each cell pellet.
7. Harvest the cells by centrifugation at 6,000 × g for 15 min at 4 °C. Carefully pour off the supernatant ( see Note 15 ) and remove any remaining drops of buffer using a Pasteur pipette attached to a vacuum line.
8. Resuspend the cells in a fi nal volume of 3 ml ice-cold 10 % glycerol, avoiding the generation of bubbles. This volume has been calculated to reach an optimal cell concentration of 2-4 × 10 10 cells/ml. 9 . Transfer 50 µl of the suspension to an ice-cold electroporation cuvette (0.2-cm gap) and test whether arcing occurs when an electrical discharge is applied with the electroporation apparatus using the conditions described in Subheading 3.2.6 , step 4 . Arcing is usually manifested by the generation of a popping sound in the cuvette during the electrical pulse. If arcing occurs, wash the cell suspension once more with 100 ml 10 % glycerol and repeat steps 7 and 8 .
10
. Dispense 100 µl aliquots of the fi nal cell suspension into sterile, ice-cold 1.5 ml microfuge tubes, freeze quickly in a dry ice-methanol bath, and transfer to a -70 °C freezer. Electrocompetent DH10B cells could be stored at -70 °C for up to 6 months without loss of transforming effi ciency.
The same standard techniques used for the cloning of DNA in conventional plasmids are applied to BACs with special considerations owing to the large size of BAC plasmids.
1. Digest the BAC vector and foreign DNA with a two-to threefold excess of the desired restriction enzymes for 3 h using the buffers supplied with the enzymes and check a small aliquot of the digestions by agarose gel electrophoresis to ensure that the entire DNA has been cleaved. Use an amount of target DNA suffi cient to yield 2 µg of the BAC vector and 0.25-0.5 µg of the desired DNA insert.
2. When two enzymes requiring different buffers are used to digest the DNA, carry out the digestion sequentially with both enzymes. Clean the DNA after the fi rst digestion by extraction with phenol-chloroform and standard ethanol precipitation or by using the Qiagen QIAEX II Gel Extraction Kit following the manufacturer's instructions for purifying DNA fragments from aqueous solutions ( see Note 16 ).
3. Purify the digested BAC vector and the DNA insert by agarose gel electrophoresis using the Qiagen QIAEX II Gel Extraction Kit following the manufacturer's instructions ( see Note 16 ).
4.
Determine the concentration of the BAC vector and the insert by UV spectrophotometry or by quantitative analysis on an agarose gel.
5. If the BAC vector was digested with only one restriction enzyme or with restriction enzymes leaving compatible or blunt ends, the digested BAC vector has to be dephosphorylated prior to its purifi cation by agarose gel electrophoresis to suppress self-ligation of the BAC vector. We recommend cleaning the DNA before the dephosphorylation reaction as described in step 2 and using shrimp alkaline phosphatase following the manufacturer's specifi cations.
1. For protruding-ended DNA ligation, mix in a sterile microfuge tube 150 ng of purifi ed digested BAC vector, an amount of the purifi ed insert equivalent to a molar ratio of insert to vector of 3:1, 1.5 µl of 10× T4 DNA ligase buffer containing 10 mM ATP, 3 Weiss unit of T4 DNA ligase, and water to a fi nal volume of 15 µl. In separate tubes, set up two additional ligations as controls, one containing only the vector and the other containing only the insert. Incubate the reaction mixtures for 16 h at 16 °C ( see Note 17 ).
2. In the case of blunt-ended DNAs, to improve the ligation efficiency use 225 ng of vector, the corresponding amount of insert, 6 Weiss unit of T4 DNA ligase, and incubate the reaction mixtures for 20 h at 14 °C.
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1.
Thaw the electrocompetent DH10B cells at room temperature and transfer them to an ice bath.
2. For each transformation, pipette 50 µl of electrocompetent cells into an ice-cold sterile 1.5 ml microfuge tube and place it on ice together with the electroporation cuvettes. 1. Mix 0.5 ml of LB freezing buffer with 0.5 ml of an overnight bacterial culture in a cryotube with a screw cap.
2. Vortex the culture to ensure that the glycerol is evenly dispersed, freeze in ethanol-dry ice, and transfer to -70 °C for long-term storage.
3. Alternatively, a bacterial colony can be stored directly from the agar plate without being grown in liquid media. Using a sterile yellow tip, scrape the bacteria from the agar plate and resuspend the cells into 200 µl of LB medium in a cryotube with a screw cap. Add an equal volume of LB freezing buffer, vortex the mixture, and freeze the bacteria as described in step 2 ( see Note 23 ).
The modifi cation of BAC clones is relatively easy and it is performed using the same techniques as for conventional plasmids with the modifi cations described in this chapter. We recommend introducing the desired modifi cations into intermediate BAC plasmids containing the different viral cDNA fragments used during the assembly of the full-length cDNA clone, and then inserting the modifi ed cDNA into the infectious clone by restriction fragment exchange. Besides standard protocols, the BAC clones can be easily and effi ciently modifi ed in E. coli by homologous recombination using a two-step procedure that combines the Red recombination system and counterselection with the homing endonuclease I-SceI [ 17 -20 ] ( see Note 24 ).
Infectious virus is recovered by transfection of susceptible cells with the full-length cDNA clone using the cationic lipid Lipofectamine 2000 as transfection reagent ( see Note 25 ). When the transfection effi ciency of the susceptible cells is very low, we recommend fi rst transfecting BHK-21 cells and then plating these 
Rescue of Recombinant Viruses
cells over a monolayer of susceptible cells to allow virus propagation. BHK-21 cells are selected because they present good transfection effi ciencies and support the replication of most known CoVs after transfection of the viral genome. The following protocol is indicated for a 35-mm-diameter dish and can be upscaled or downscaled if desired ( see Note 26 ). 3. During this incubation period, wash the BHK-21 cells once with growth medium without antibiotics and leave the cells in 1 ml of the same medium per dish.
4. Add the 500 µl of the DNA-Lipofectamine 2000 mixture onto the washed cells and mix by rocking the plate back and forth. Incubate the cells at 37 °C for 6 h ( see Note 30 ).
5.
Remove the transfection medium, wash the cells with trypsin-EDTA solution, and detach the cells using 300 µl of trypsin-EDTA solution.
6. Add 700 µl of growth media to collect the cells and reseed them over a confl uent monolayer of susceptible cells containing 1 ml of normal growth medium.
7. Incubate at 37 °C until a clear cytopathic effect was observed.
8. Analyze the presence of virus in the supernatant by titration.
9. Clone the virus by three rounds of plaque purifi cation and analyze the genotypic and phenotypic properties of the recovered virus.
Notes
1. E. coli DH10B strain is a recombination-defective strain used for the propagation of BACs to avoid unwanted rearrangements.
2. SOB medium should be Mg 2+ -free to avoid arcing during the electroporation step.
3. The Huh-7 cell line has never been deposited at ATCC but it can be purchased from the Japanese Collection of Research Bioresources (JCRB) Cell Bank. 4 . In case that a restriction site present in the BAC plasmid was selected, it must be removed in the plasmid by the introduction of silent mutations.
5.
The silent mutations introduced in the viral genome to generate new restriction sites or to abrogate preexisting ones can be used as genetic markers to identify the virus recovered from the infectious clone.
6.
To reduce the number of undesired mutations, perform all PCR reactions with a high-fi delity polymerase, according to the manufacturer's instructions.
7. The CMV promoter and the BGH termination and polyadenylation sequences can be amplifi ed from pcDNA3.1. Alternatively, these sequences together with the HDV ribozyme could be amplifi ed from plasmid pBAC-TGEV 5ʹ-3ʹ that is available from the authors upon request.
8. In general, the cloning of CoV full-length cDNAs in BACs allows the stable propagation of the infectious clone in E. coli DH10B cells. If a residual toxicity, characterized by a small colony phenotype and a delay in the bacterial growth, is observed during the assembly of the infectious clone, we recommend inserting the DNA fragment responsible for this toxicity in the last cloning step to minimize the toxicity problem.
9.
Cultures of BAC transformed bacteria should be grown from a single colony isolated from a freshly streaked selective plate. Subculturing directly from glycerol stocks or plates that have been stored for a long time may lead to loss of the construct. 17. The large size of the BAC vectors reduces the ligation efficiency. To increase this effi ciency, it is essential to use larger amounts of vector, insert, and T4 DNA ligase than when using conventional plasmids.
18. Most electroporation machines contain programs with defi ned parameters for transforming specifi c cell types. In this case, choose the program containing the conditions closest to those described in this protocol. 19 . The presence of salt increases the conductivity of the solution and could cause arcing during the electrical pulse, drastically reducing the transformation effi ciency. If arcing occurs, use a smaller amount of the ligation reaction in the electroporation or remove salt from the DNA using any commercial kit or by extraction with phenol-chloroform followed by precipitation with ethanol and 2 M ammonium acetate. 20 . Plating volumes higher than 200 µl of electroporated cells on a single plate may inhibit the growth of transformants owing to the large number of dead cells resulting from electroporation.
If only small numbers of transformant colonies are expected, it is recommended to spread 200 µl-aliquots of the electroporated cells on different plates.
21.
A mix of small and large colonies indicates that the cloned DNA fragment presents some toxicity when amplifi ed in E. coli . Choose the small colonies, which may contain the correct insert, and always grow the bacteria containing this recombinant BAC plasmid at 30 °C to minimize the toxicity problem.
In this case, we strongly recommend inserting this toxic DNA fragment into the infectious clone in the last cloning step, in order to reduce the manipulation and minimize the possibility of introducing unwanted mutations. Infectious BAC cDNA clones presenting a residual toxicity should be grown at 30 °C.
22. It is important to avoid overloading the reaction by adding too much bacteria, which may alter the ionic balance of the reaction and inhibit the amplifi cation by the Taq polymerase.
23. We recommend to use this storage method for BAC clones that present a residual toxicity and are not fully stable when amplifi ed in E. coli .
24. The Red recombination system combined with counterselection with I-SceI endonuclease results in an accurate and highly effi cient method to introduce insertions, deletions, or point mutations in BAC clones without retention of unwanted foreign sequences.
25. The transfection of BACs containing large inserts into mammalian cells has been optimized in our laboratory and the best transfection effi ciencies were provided using Lipofectamine 2000 as transfection reagent.
26. All work involving MERS-CoV has to be performed in a Biosafety Level 3 (BSL3) laboratory, following the guidelines of the European Commission and the National Institutes of Health (NIH) of the USA.
27. Do not add antibiotics to media during transfection as this may decrease transfection activity. A healthy cell culture is critical for an effi cient transfection. The use of low passagenumber cells is recommended.
28. Use a BAC DNA isolated with the Qiagen Large-Construct Kit since a DNA preparation of high purity is required in the transfection step.
29. Opti-MEM I Reduced Serum Medium is recommended for dilution of the cationic lipid Lipofectamine 2000 reagent prior to complexing with DNA, although other media without serum may also be used. However, owing that some serumfree media formulations can inhibit cationic lipid-mediated transfection, test any new serum-free medium for compatibility with the transfection reagent prior to use. Some media formulations that have been found to inhibit cationic lipid-mediated transfection are CD 293 Medium, 293 SFM II, and VP-SFM.
30. If susceptible cells are directly transfected, incubate them at 37 °C until the cytopathic effect is observed and proceed to clone and characterize the recovered virus. In this case, optimization of the transfection of the desired cells with the BAC clone using Lipofectamine 2000 should be required. For transfection optimization, use a similar size plasmid expressing GFP. This plasmid is available from the authors upon request.
